Which peripartum cardiomyopathy trial (BOARD trial / IPAC study) identified bromocriptine as a potential treatment by targeting prolactin-mediated 16-kDa cardiotoxic cleavage?
- A BOARD trial ✓
- B IPAC cohort study
- C HPAAT trial
- D ESC EURO-Observational study
Correct answer: A. BOARD trial
Explanation
The BOARD trial (BROmocriptine in peripartum cardiomyopathy) was a prospective randomised pilot trial demonstrating that bromocriptine (a dopamine agonist that suppresses prolactin secretion) added to standard heart failure therapy improved left ventricular recovery in peripartum cardiomyopathy. The biological rationale is that cathepsin D cleaves prolactin into a cardiotoxic 16-kDa fragment; blocking prolactin release with bromocriptine is protective. IPAC was a US registry/cohort study defining natural history.
Reference: Williams Obstetrics, 26th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.